ライフサイエンスコーパス: OVA

1 OVA also induced IL-33 and ST2 protein expression.

2 OVA asthma model in MUC1 KO mice was resistant to the an

3 OVA immunization of C3ar1(-/-)C5ar1(-/-) mice elicited I

4 OVA T-cell receptor-specific T cells were T(H)22 polariz

5 OVA- and house dust mite (HDM)-induced murine asthma mod

6 OVA-IgE and OVA-IgG1 serum levels were not significantly

7 OVA-induced increases in bronchoalveolar lavage lymphocy

8 OVA-induced increases in DC and CD4(+) T-cell recruitmen

9 OVA-sensitized BRP-39(-/-) mice showed decreased epiderm

10 OVA-sensitized mice with SD had more severe airway infla

11 OVA-specific CD8(+) T cells transferred to mice immunize

12 In the absence of IL-15, OVA-challenged mice exhibited enhanced bronchial eosinop

13 (OVA) consisting of OVA residues 323 to 339 (OVA(323-339)).

14 In WT mice, PM2.5 + OVA exacerbated OVA-related lung eosinophilia.

15 In adulthood, OVA-exposed females showed an increase in male-typical m

16 i.v. 48 h before challenge with aerosolized OVA.

17 After OVA recall, specific IgE concentrations were reduced by

18 hate (S1P) are significantly augmented after OVA treatment in mice.

19 AT) 4 and STAT6 signaling in the lungs after OVA sensitization.

20 -reverted murine BCR that was selected after OVA immunization of mice, whereas conventional assays fa

21 murine CMV (MCMV) expressing the cognate Ag OVA.

22 PLA(2)) administered with the incomplete Ag OVA leads to an Ag-specific immune response.

23 Foxp3(+) Treg in response to a cutaneous Ag (OVA).

24 tocol (CD4 blockade) and the same target Ag (OVA) achieves Foxp3-dependent transplantation tolerance

25 ctive effect of intranasal IRL201104 against OVA-induced eosinophilia persisted for up to 20 days pos

26 duction in airway hyperresponsiveness (AHR), OVA allergen-challenged Ormdl3(Delta2-3/Delta2-3)/CC10 m

27 C57BL/6 mice were challenged in an allergic OVA model, and parameters of inflammation were examined.

28 upregulated in conjunctival tissue during an OVA-induced allergic response.

29 developed enhanced allergic responses in an OVA-induced model of AAD.

30 A-biotin-filariae was compared to that of an OVA-bound nanoparticulate carrier co-delivered with a Cp

31 g OVA-expressing S. aureus strain to analyze OVA-specific T cell responses, we demonstrated that prim

32 VA sensitization prevented food anaphylaxis, OVA-specific IgE production, and intestinal mast cell ex

33 In a proof-of-concept study, Der p 1 and OVA levels were determined in 100 human breast milk samp

34 In ST2 knockout mice, IL-33 and OVA induced airway hyperresponsiveness and eosinophilic

35 In IL-33 knockout mice, the IL-33- and OVA-induced airway hyperresponsiveness and eosinophilic

36 acterial lysate, recombinant P1 adhesin, and OVA.

37 ouse dust mice and Alternaria alternata) and OVA-induced models of active anaphylaxis to determine th

38 e we report that mice with severe asthma and OVA-sensitized/challenged mice had increased PTX3 levels

39 OVA-IgE and OVA-IgG1 serum levels were not significantly altered by

40 FcRn)-dependent transfer of maternal IgG and OVA immune complexes (IgG-IC) via breast milk and induct

41 We then administered MPO- and OVA-conjugated apoptotic splenocytes (MPO-Sps and OVA-Sp

42 onjugated apoptotic splenocytes (MPO-Sps and OVA-Sps, respectively) to mice and compared their effect

43 t not S pneumoniae, infection augmented anti-OVA IgE antibody responses.

44 In OT-II CD4(+) anti-OVA TCR transgenic mice sensitized to ovalbumin antigen,

45 T cells mediated in vivo suppression of anti-OVA antibody production.

46 pendent tolerance when the Ag is provided as OVA-aluminum hydroxide.

47 ized, but nonphysiologic, model Ags, such as OVA and hemagglutinin.

48 IgG1 antibody ratio, indicative of augmented OVA-specific Th1-biased immunity.

49 ing the efficacy of a model vaccine in a B16-OVA melanoma mouse model.

50 ith tetanus vaccine were challenged with B16.OVA tumors and treated with the newly developed hybrid T

51 ctively inhibits tumour growth in the B16F10-OVA and human papilloma virus-E6/E7 tumour models in mic

52 erred into mice bearing established TGF-beta-OVA-expressing thymomas, produce high amounts of IFN-gam

53 The coacervate complex between OVA and AL was evaluated based on electrostatic interact

54 ence in the expression of IL-17 mRNA between OVA-treated skin of VAN and VAD mice.

55 f sPLA(2)-X that result in the type 2-biased OVA-specific adaptive immune response in the lung were d

56 The best mass ratio for the biopolymers (OVA:AL) was 4:1 at pH 3.8, and the complex exhibited a t

57 gG immune complexes during pregnancy boosted OVA uptake by fetal dendritic cells (DCs).

58 Both OVA and HDM-induced airway diseases were more severe in

59 lution exceeding 1.0 and CVs of 8.4% for BSA-OVA and 2.4% for OVA-TI, with comparable reproducibility

60 d animals compared with control animals, but OVA-specific IgG responses were unaffected.

61 cells and the prevention of food allergy by OVA exposure through breast milk.

62 Breastfeeding by OVA-sensitized mothers or maternal supplementation with

63 L1 mediates the development of AD induced by OVA, affecting Th2 inflammation, M2 macrophage activatio

64 calis-induced DCs showed reduction in CD4(+) OVA-specific OT-II T cell proliferation.

65 s HA-expressing 4T1 mammary carcinoma cells, OVA-expressing EG7 lymphoma cells and CMS5 MCA-induced f

66 We demonstrated with chicken OVA-specific TCR-transgenic mice that the same tolerizin

67 Increased numbers of circulating, OVA-specific CD4(+) T cells also were observed in pigs t

68 Human breast milk containing OVA-IgG-IC induced tolerance in humanized FcRn mice.

69 In contrast, OVA-exposed males showed evidence of dysmasculinization,

70 flow-sorted CXCR5CXCR3 (and not CXCR3CXCR5) OVA-primed OT-I CD8 T cells mediated in vivo suppression

71 ed with the OVA(257-264) peptide antigen (DC-OVA) leads to a higher expansion of OVA-specific T cells

72 We report that orally delivered OVA rapidly disseminates through the blood of Muc2(-/-)

73 y assessing severity and onset of diarrhoea, OVA-specific antibody production, mast cell number and a

74 tigen processing (based on degradation of DQ-OVA, a substrate for proteases which upon hydrolysis is

75 vaccine constructs effectively inhibited EG7-OVA tumor growth in mice, however only treatment with th

76 ion of established primary or metastatic EG7.OVA, B16F10, and MC38 tumors; combination with anti-PD-1

77 Using a chicken egg OVA-expressing S. aureus strain to analyze OVA-specific

78 red to recognize a single ovalbumin epitope (OVA(457-462)).

79 In WT mice, PM2.5 + OVA exacerbated OVA-related lung eosinophilia.

80 CD4(+)-T cells and cMy-mOVA mice expressing OVA on cardiomyocytes were crossed.

81 ificantly reduced within the lungs following OVA or HDM challenge.

82 1.0 and CVs of 8.4% for BSA-OVA and 2.4% for OVA-TI, with comparable reproducibility to glass microde

83 eptor (TSLPR) on CD4 T cells is required for OVA-induced lung inflammation, DCs have also been shown

84 LPS-free OVA does not recapitulate any of the precursor signs of

85 Inflammatory cytokine levels in BALF from OVA-sensitized, M pneumoniae-infected or S pneumoniae-in

86 tive transfer of splenic CD8(+) T cells from OVA-sensitized WT mice suppressed the enhancement of eos

87 gues of MHC-II-binding peptides derived from OVA, in which at least one alpha-amino acid residue was

88 A CD8(+) T cell epitope peptide from OVA (CSIINFEKL) and CpG were co-conjugated to nanopartic

89 Furthermore, OVA-exposed lung Ptx3(-/-) CD4 T cells exhibit an increa

90 Furthermore, treatment of E.G7-OVA tumor-bearing mice with Lp/OVA/StII significantly re

91 hea, hypothermia, increased hematocrit, high OVA-specific serum IgE, and MCPT-1 levels in wt mice.

92 n, intranasal OVA application induced higher OVA-specific IgG1 and total IgE in serum, and increased

93 In OVA-induced C57BL/6 mouse AD model, compared with VAN gr

94 ry cells and the levels of IL-13 and IL-4 in OVA-challenged airways.

95 IL-6- and IL-23-producing dendritic cells in OVA-exposed Ptx3(-/-) mice compared with those in wild-t

96 levels, more IL-4, IL-13 mRNA expression in OVA-sensitized skin, and lower Th1 immune response, incl

97 IL-13 but suppressed IFN-gamma expression in OVA-specific CD4 Tcon cells.

98 these effects of SEA and IL-13 expression in OVA-specific T cells.

99 i-S pneumoniae antibody levels were found in OVA-sensitized animals.

100 n expression levels of BRP-39 were higher in OVA-sensitized WT mice than in control mice.

101 However, in OVA-induced ckit(w-sh/w-sh) mouse AD model, we did not f

102 whereas these cells remained inactivated in OVA sensitization model.

103 ncreased TH2-mediated airway inflammation in OVA or HDM murine models of asthma.

104 esions and reveal the significance of LPS in OVA used in most studies, thus mimicking natural antigen

105 Furthermore, deletion of MCPIP1 in OVA- or HDM-specific T cells leads to significantly incr

106 Comparable differences occurred in OVA-immunized muMT recipients of WT, C3ar1(-/-)C5ar1(-/-

107 s in VAS group and VAN group were similar in OVA-induced AD model mice.

108 e expression and phosphorylation of STAT6 in OVA-exposed mice, whereas Lyn knockdown increased STAT6

109 ve transfer-induced immunogenic tolerance in OVA-sensitized mice might not be due to SOCS3 gene deple

110 n, immunization with ovalbumin (OVA) induced OVA-specific B cells only in human IL-6 knock-in mice.

111 ssentially ablated in M pneumoniae-infected, OVA-sensitized animals.

112 iltration and decreased AHR after intranasal OVA challenge.

113 er epithelial barrier disruption, intranasal OVA application induced higher OVA-specific IgG1 and tot

114 ce were exposed to a first set of intranasal OVA challenge under SD or healthy sleep (HS) conditions,

115 ed airway inflammation and AHR on intranasal OVA challenge.

116 lergic asthma was induced by intraperitoneal OVA/alum sensitization followed by repeated OVA airway c

117 Consequently, Lp/OVA/StII induced a more potent effector function, as sho

118 was encapsulated with OVA into liposomes (Lp/OVA/StII) to assess their efficacy to induce a CTL respo

119 cells transferred to mice immunized with Lp/OVA/StII experienced a greater expansion than when the r

120 ecific CTL response to that observed with Lp/OVA/StII or vesicles encapsulating recombinant StI or th

121 tment of E.G7-OVA tumor-bearing mice with Lp/OVA/StII significantly reduced tumor growth being more n

122 Maternal OVA sensitization prevented food anaphylaxis, OVA-specif

123 emonstrate that CCL7 is required for maximal OVA-induced ocular anaphylaxis, mast cell recruitment in

124 ression by ovalbumin (OVA)-primed monoclonal OVA-specific t-cell receptor transgenic CD8+ T cells (OT

125 Accordingly, more OVA-specific IgG1-secreting cells are present in spleen

126 Moreover, OVA challenge in sensitized rats was associated with inc

127 Moreover, OVA-sensitized mice treated intranasally with 20 ng/kg o

128 ely suppress their ability to polarize naive OVA-TCR transgenic CD4(+) T cells into IFN-gamma-secreti

129 examined for their ability to polarize naive OVA-TCR transgenic CD4(+) T cells.

130 nitrated OVA (nOVA), and maximally nitrated OVA (nOVAmax) were performed before mice were immunized

131 ergy-preventive treatment with OVA, nitrated OVA (nOVA), and maximally nitrated OVA (nOVAmax) were pe

132 No OVA-specific antibodies were induced in response to TAC

133 Presentation of nonsecreted OVA (GFPOVA) by steady-state LCs resulted in transient a

134 Sensitization with OVA plus SEA but not OVA alone induced asthma, and SEA exacerbated asthma ind

135 MPO-Sp but not OVA-Sp administration increased MPO-specific, peripheral

136 We show that a single application of OVA to mouse skin initiates remodeling and cellular infi

137 Application of OVA/IgG immune complexes during pregnancy boosted OVA up

138 IgE and IgG1 concentrations in the blood of OVA-sensitized Cyp27b1-KO mice compared with wild-type l

139 l epitope from ovalbumin (OVA) consisting of OVA residues 323 to 339 (OVA(323-339)).

140 +) cells from OT-II mice restored effects of OVA on lymphocytes, eosinophils, IL-13, IL-5, and mucous

141 Examination of OVA-challenged IL-15Ralpha(-/-) animals revealed a simil

142 igen (DC-OVA) leads to a higher expansion of OVA-specific T cells in response to vaccination done in

143 We found that expression of OVA resulted in fatal autoimmunity and in prevention of

144 ated pTreg were sufficient for inhibition of OVA-induced AHR in an Ag-driven murine model of AAD.

145 hing the levels induced by s.c. injection of OVA/alum (SCIT).

146 y three intraperitoneal (i.p.) injections of OVA/alum.

147 demonstrate that PorB increases the level of OVA in the endo-/lysosomal cellular compartment of BMDCs

148 ment and cytokine generation in the lungs of OVA-challenged mice were attenuated by intrapulmonary pr

149 erresponsiveness in an experimental model of OVA-induced asthma.

150 13 acted on DCs from draining lymph nodes of OVA-sensitized skin to selectively suppress their abilit

151 of mast cells and increased phagocytosis of OVA by CX3CR1(hi) macrophages.

152 The immunization potential of OVA-biotin-filariae was compared to that of an OVA-bound

153 ic Treg or CD4 Tcon cells in the presence of OVA and SEA.

154 ent) or protein (ovalbumin >90% reduction of OVA present) and organic solvent (ethanol >95% reduction

155 or in MC, remarkably mitigates all signs of OVA-mediated remodeling and MC activation.

156 (OVA) in Was(-/-) mice induced low titers of OVA-specific IgE compared to the WT-OVA/alum model.

157 es involving stable and unstable versions of OVA model Ags displaying defective ribosomal protein-dep

158 In wild-type mice, IL-33 or OVA induced similar airway hyperresponsiveness and eosin

159 Based on the presence of Der p 1 and/or OVA in human breast milk, we identified groups of lactat

160 (+) T cells from mice treated with MPO-Sp or OVA-Sp to recipient mice with established anti-MPO autoi

161 e developed allergic diarrhea following oral OVA challenge.

162 Further, the administration of oral OVA to Muc2(-/-) mice led to its presentation by thymic

163 Repeated oral OVA challenge resulted in diarrhea, hypothermia, increas

164 Ovalbumin (OVA)-sensitized C57BL/6 mice were exposed to a first set

165 Ovalbumin (OVA)-specific, staphylococcal enterotoxin A (SEA)-nonrea

166 cheally challenged with PM2.5 +/- ovalbumin (OVA) four times at 2-week intervals.

167 induced by epicutaneous allergen ovalbumin (OVA) sensitization.

168 The model allergen ovalbumin (OVA) was nitrated in different nitration degrees, and th

169 c responses to a second allergen, ovalbumin (OVA), in mice sensitized dually to OVA and Fel d 1.

170 nce to a bystander food allergen, ovalbumin (OVA).

171 lymph nodes of tape-stripped and ovalbumin (OVA)-sensitized skin were examined for their ability to

172 A model antigen ovalbumin (OVA) and TLR agonists imiquimod and monophosphoryl Lipid

173 und and released proteins such as ovalbumin (OVA) or the major cat allergen Fel d 1.

174 rgic lung inflammation induced by ovalbumin (OVA) in mice and by house dust mite (HDM) in guinea pigs

175 g a murine model of AD induced by ovalbumin (OVA), we investigated Th2 immune responses, M2 macrophag

176 Antibody suppression by ovalbumin (OVA)-primed monoclonal OVA-specific t-cell receptor tran

177 The phenotype of circulating, ovalbumin (OVA)-specific T cells also was examined in HEWP challeng

178 flammation induced by chicken egg ovalbumin (OVA) in mice.

179 crosslinked protein, chicken egg ovalbumin (OVA), in the absence of an external adjuvant.

180 trinsic AD, eAD), and established ovalbumin (OVA) percutaneous sensitized AD model and passive cutane

181 First, ovalbumin (OVA) antigen-specific cytotoxic T-cells (CTLs) were incu

182 ceptor (TCR) with specificity for ovalbumin (OVA) on CD4(+)-T cells and cMy-mOVA mice expressing OVA

183 logous CD4(+) T cell epitope from ovalbumin (OVA) consisting of OVA residues 323 to 339 (OVA(323-339)

184 In ovalbumin (OVA)-expressing E.G-7 tumor-bearing immune-deficient mic

185 (BMDCs) on airway inflammation in ovalbumin (OVA)-sensitized asthmatic mice.

186 attempted by repeated intranasal ovalbumin (OVA) applications in Naive mice.

187 lated via complex coacervation of ovalbumin (OVA) and sodium alginate (AL), and the microcapsule prop

188 Oral administration of ovalbumin (OVA) in Was(-/-) mice induced low titers of OVA-specific

189 An asthma model of ovalbumin (OVA) was used in MUC1 KO and WT C57BL/6 mice according t

190 We assessed the impact of ovalbumin (OVA)-induced allergic inflammation on the appearance of

191 ne the effect of Ptx3 deletion on ovalbumin (OVA)-induced allergic inflammation in a murine model of

192 nd B cell-deficient mice received ovalbumin (OVA) intranasally before mating.

193 nd activity were evaluated in the ovalbumin (OVA) and house dust mite (HDM) murine models.

194 ivated using dimaprit in both the ovalbumin (OVA) and house dust mite extract (HDM) murine models of

195 proteins (Trypsin Inhibitor (TI); Ovalbumin (OVA); Bovine Serum Albumin (BSA)), we observe resolution

196 C3H/HeJ mice were sensitized to ovalbumin (OVA) orally or through the skin and treated with EPIT us

197 d E coli BL21_HTW were gavaged to ovalbumin (OVA) sensitized and challenged mice to investigate the e

198 Pregnant rats were sensitized to ovalbumin (OVA), bred, and challenged intranasally with OVA on gest

199 5ac transcript in mice exposed to ovalbumin (OVA).

200 aling were chronically exposed to ovalbumin (OVA).

201 a type 2 inflammatory reaction to ovalbumin (OVA).

202 immunized intraperitoneally with ovalbumin (OVA) and challenged intranasally with antigen.

203 ha(-/-) mice were sensitized with ovalbumin (OVA) and then infected with M pneumoniae or Streptococcu

204 ously sensitized female mice with ovalbumin (OVA) followed by epicutaneous sensitization and oral cha

205 ntraperitoneal sensitization with ovalbumin (OVA) in combination with intranasal (i.n) exposure to OV

206 C mice were first sensitized with ovalbumin (OVA) in the presence of alum.

207 In addition, immunization with ovalbumin (OVA) induced OVA-specific B cells only in human IL-6 kno

208 e recipient mice, challenged with ovalbumin (OVA) or house dust mite (HDM), and accessed for TH2 infl

209 re sensitized and challenged with ovalbumin (OVA), and the development of AAD was ascertained by exam

210 When pulsed with ovalbumin (OVA), the E. faecalis-induced DCs showed reduction in CD

211 sed in whole lungs from mice with ovalbumin (OVA)-induced allergic airway inflammation (AAI).

212 re sensitized and challenged with ovalbumin (OVA).

213 ld-type mice were sensitized with ovalbumin (OVA).

214 r uptake of model cancer antigen (ovalbumin, OVA) by THP-1-differentiated macrophage-like cells in vi

215 PO(409-428)) or a control ovalbumin peptide (OVA(323-339)) to splenocytes and induced apoptosis in th

216 okine production to RSV as well as a primary OVA response.

217 e cell infiltration into the lung in the rat OVA model of asthma, on the other hand, appears to be de

218 ciency of approximately 94.12% in the ratio (OVA:AL) of 1:1.

219 WT, but not IL-22-deficient, T-cell receptor OVA-specific T cells, which secrete both IL-17A and TNF-

220 OVA/alum sensitization followed by repeated OVA airway challenges.

221 9cRA applied together with repeated OVA challenge transiently increased specific serum IgA,

222 sleep (HS) conditions, followed by a second OVA challenge, 1 week apart.

223 ronchoalveolar lavage (BAL) compared to sham-OVA mice.

224 SHAS-OVA were taken up by human monocyte-derived dendritic ce

225 A released from subcutaneously injected SHAS-OVA led to a sustained stimulation of both CD4(+) and CD

226 Allergen-specific immunotherapy with SHAS-OVA as compared to soluble OVA resulted in similar humor

227 sulated with OVA into Lp, elicited a similar OVA-specific CTL response to that observed with Lp/OVA/S

228 therapy with SHAS-OVA as compared to soluble OVA resulted in similar humoral responses but in a highe

229 Compared to soluble OVA-based vaccine, OVA loaded NPs demonstrated faster an

230 ed either CD4(+) cells from ROCK2-sufficient OVA TCR transgenic (OT-II) mice or saline i.v. 48 h befo

231 ature drop was then monitored after systemic OVA challenge in uninfected mice and in mice infected ch

232 induced significantly higher IgG levels than OVA, matching the levels induced by s.c. injection of OV

233 and CD4(+) effector T cell populations than OVA-sensitized WT mice.

234 lergic asthmatic inflammation, we found that OVA released from subcutaneously injected SHAS-OVA led t

235 The OVA-specific CD4 T cells were then analyzed for IL-13 an

236 dent on TSLP in both the MC903 model and the OVA sensitization model.

237 CD4(+) T(Pam3) cells encoding the OVA-specific TCR OT2, when transferred into mice bearing

238 esulted in more severe airway disease in the OVA model, while dimaprit treatment significantly reduce

239 duced in nonobese asthma patients and in the OVA murine model.

240 ed cytokine secretion from lung cells in the OVA respiratory inflammation mouse model.

241 In the OVA-induced allergic response, the numbers of conjunctiv

242 e whole lung was significantly higher in the OVA-sensitized and -challenged mice which was associated

243 T1 mice are engineered to recognize only the OVA(457-462) epitope, the above observations have demons

244 Our findings exhibited that the OVA challenge in sensitized rats induced anxiety-like be

245 llowing vaccination with DCs loaded with the OVA(257-264) peptide antigen (DC-OVA) leads to a higher

246 ous autoimmunity despite the fact that their OVA-specific CD4(+)-T cells were not anergic.

247 These OVA-specific antibodies displayed the highest frequency

248 In contrast to OVA and nOVA, the conformation of nOVAmax was substantia

249 valbumin (OVA), in mice sensitized dually to OVA and Fel d 1.

250 he respiratory epithelium of mice exposed to OVA or HDM.

251 in unchanged in MC-deficient mice exposed to OVA.

252 promoter region of Muc5ac in mice exposed to OVA.

253 ombination with intranasal (i.n) exposure to OVA.

254 DClps migrated to OVA-sensitized lungs with higher efficiency than immatur

255 0 T cell binding to DCs and proliferation to OVA peptide.

256 (+)IL-10(+) B cells, whereas the response to OVA was associated with a marked reduction in numbers of

257 nockout (KO) mice following sensitization to OVA or intestinal infection with Heligmosomoides polygyr

258 ced following a protocol of sensitization to OVA.

259 Induction of tolerance to OVA was achieved through simultaneous exposure to both a

260 Foxp3-dependent transplantation tolerance to OVA-expressing skin grafts, but Foxp3-independent tolera

261 d treated with the newly developed hybrid TT-OVA-PeptiCRAd containing both tetanus toxoid- and tumor-

262 ions during therapy compared to unconjugated OVA.

263 re reduced compared with those in uninfected OVA-sensitized control animals.

264 minute post-challenge compared to uninfected OVA-challenged controls.

265 dults and were highly efficient in taking up OVA/IgG immune complexes.

266 Upon OVA challenge, CD-fed mice developed strong AHR and airw

267 sults demonstrate that it is possible to use OVA:AL as encapsulating agents to protect bioactive comp

268 through the skin and treated with EPIT using OVA-Viaskin patches or oral immunotherapy using OVA.

269 -Viaskin patches or oral immunotherapy using OVA.

270 Compared to soluble OVA-based vaccine, OVA loaded NPs demonstrated faster antibody affinity mat

271 ced lung eosinophilia and suppressed ex vivo OVA-stimulated cytokine secretion from lung cells in the

272 When OVA(323-339) was expressed as a fusion with green fluore

273 atory molecule CD86 on cultured MCs, whereas OVA peptide-loaded MCs increased OT-II CD4(+) T cell pro

274 ization and subsequent airway challenge with OVA.

275 /-) mice were sensitized and challenged with OVA and bronchoalveolar lavage fluid, and the lungs were

276 cytes in the lung lumen when challenged with OVA and, in contrast, an accumulation of these cells in

277 owever, when these mice were challenged with OVA by gene gun immunization in the contraction phase of

278 r together with SEA and then challenged with OVA or CDE.

279 days or were sensitized and challenged with OVA over 21 d.

280 Mice were orally challenged with OVA to induce anaphylaxis.

281 eeks and then sensitized and challenged with OVA.

282 Prior to oral challenges with OVA, mice were subjected to VGX or VNS.

283 ory T cells after in vitro coincubation with OVA/IgG-containing AF.

284 chodactyla helianthus, was encapsulated with OVA into liposomes (Lp/OVA/StII) to assess their efficac

285 the StI mutant StI W111C, encapsulated with OVA into Lp, elicited a similar OVA-specific CTL respons

286 on the immune response by immunization with OVA and induction of chronic graft-versus-host disease i

287 size of the GCs following immunization with OVA protein in complete Freund's adjuvant.

288 lethal dose of DENV2 and mice immunized with OVA (negative control).

289 OVA), bred, and challenged intranasally with OVA on gestational day 15, which produced robust allergi

290 By contrast, in the model with OVA sensitization, LCs inhibited T(FH)/GC response and s

291 n and oral challenge of their offspring with OVA.

292 Sensitization with OVA plus SEA but not OVA alone induced asthma, and SEA e

293 reg cell depletion before sensitization with OVA plus SEA.

294 lenge of mice epicutaneously sensitized with OVA elicited in the lungs Il22 mRNA expression, IL-22 pr

295 n, mice were intratracheally sensitized with OVA or cat dander extract (CDE) alone or together with S

296 ng proteins expressed in C. trachomatis with OVA(323-339), we can begin to understand how protein exp

297 ) T cells transferred from mice treated with OVA-Sp) were protected from anti-MPO autoimmunity and GN

298 Allergy-preventive treatment with OVA, nitrated OVA (nOVA), and maximally nitrated OVA (nO

299 etion studies or the adoptive transfer of WT OVA-specific CD4(+) T cells to WT or Pag1(-/-) recipient

300 n adjuvant-based model in wild-type mice (WT-OVA/alum).

301 iters of OVA-specific IgE compared to the WT-OVA/alum model.